Online Management of Breast Diseases Patient Education |  Physician Guidelines |  Treatment Index
News |  TransMed |  E-Mail |  Disclaimer

Onc.Protocol:TAMOXIFEM

 

 

ONCOLOGIC PROTOCOL

NOVALDEX (TAMOXIFEN)

MAJOR INDICATIONS: HORMONAL TREATMENTS FOR BREAST CANCER (ALL STAGES)
IDENTIFICATION: Tamoxifen (Nolvadex)
This drug has been approved by the FDA (Food and Drug Administration) for the treatment of breast cancer.
Dose: 10 mg (1 tablet) twice per day.
Route: Given orally
Duration and timing: Treatment for adjuvant therapy is continued to a maximum of 5 years. In the treatment of stage IV disease treatment is continued until disease progression.
Possible Side effects:
  • Hematopoetic: decrease in blood cells, especially white cells (neutropenia) but also red cells (anemia) and or platelets (thrombocytopenia)
  • Gastrointestinal: possible nausea and vomiting (which may be decreased or prevented with medications).
  • Systemic: menopausal symptoms (hot flashes, night sweats, menstrual irregularity), bone or tumor pain, hypercalcemia (high calcium levels), hyperlipidemia (high lipid levels).
  • Gynecologic: vaginal bleeding, vaginal discharge, rare instances of endometrial cancer
  • Fertility: adverse effect on fertility is known; this drug should not be taken by women who are pregnant or breast feeding.
  • Respiratory: instances of pulmonary embolism have occurred (blood clot going to the lung).
  • Ocular: visual disturbances, cataracts, corneal deposits, optic neuritis (swelling of the optic nerve) and retinopathy (disturbances in the function of the retina).
  • Hepatic: elevated liver enzymes, hepatitis, hepatic necrosis (liver death) and fatty changes in the liver.
  • Other: increased risk of developing blood clots. In males decreased libido (sex drive) and impotence has been reported.

Back gif

 

1997 - TransMed Network